References of "Aerts, Joël"
     in
Bookmark and Share    
Peer Reviewed
See detailp-[18F]MPPF, a fluoro analog of WAY-100635 for visualisation of 5-HT1A receptors in cat.
Le Bars, D.; Ginovart, N.; Hassoun, W. et al

in Journal of Labelled Compounds & Radiopharmaceuticals (1999), 42

Detailed reference viewed: 9 (2 ULg)
Peer Reviewed
See detailThe synthesis of 6-[18F]fluoro-L-dopa by chiral catalytic phase-transfer alkylation.
Lemaire, Christian ULg; Guillouet, S.; Plenevaux, Alain ULg et al

in Journal of Labelled Compounds & Radiopharmaceuticals (1999), 42

Detailed reference viewed: 17 (1 ULg)
Peer Reviewed
See detailIn vivo studies of p-[18F]MPPF metabolites in human.
Damhaut, Ph.; Plenevaux, Alain ULg; Lemaire, Christian ULg et al

in Journal of Labelled Compounds & Radiopharmaceuticals (1999), 42

Detailed reference viewed: 7 (2 ULg)
Peer Reviewed
See detail5-HT1A receptor distribution in the human brain: preliminary PET data with p-[18F]MPPF.
Fuchs, Sonia ULg; Plenevaux, Alain ULg; Degueldre, Christian ULg et al

in Society for Neuroscience / Abstracts (1999), 25

Detailed reference viewed: 14 (0 ULg)
Full Text
Peer Reviewed
See detailp-[18F]MPPF, 5-HT1A antagonist: comparison to [3H]8-OH-DPAT with autoradiography
Plenevaux, Alain ULg; Weissmann, D.; Lemaire, Christian ULg et al

in Society for Neuroscience / Abstracts (1999)

p-MPPF 4-(2’-methoxyphenyl)-1-[2’-[N-(2’’-pyridinyl)-p-fluorobenzamido] ethyl]piperazine is the para-fluorobenzoyl analog of the highly selective 5-HT1A antagonist WAY-100635. The one step procedure used ... [more ▼]

p-MPPF 4-(2’-methoxyphenyl)-1-[2’-[N-(2’’-pyridinyl)-p-fluorobenzamido] ethyl]piperazine is the para-fluorobenzoyl analog of the highly selective 5-HT1A antagonist WAY-100635. The one step procedure used to label p-MPPF with fluorine-18 (cyclotron produced positron emitter of 110 min half-life) leads to a radiopharmaceutical compound easily prepared on a large scale. The preliminary evaluations conducted in rats and cats are good reason to consider p-[18F]MPPF as an interesting reversible radioligand to study the 5-HT1A receptor family in humans with positron emission tomography (PET). In this paper we report a careful comparison between p-[18F]MPPF and [3H]8-OH-DPAT with autoradiography and quantitative densitometry in the same animal. All experiments were conducted in Sprague Dawley male rats. For p-[18F]MMPF, the results were obtained ex-vivo after an intravenous injection of high specific activity radioligand (0.8-1.5 Ci/µmol) in vigil (no anesthesia), free moving and unstressed animals. For the purpose, permanent cannulation of the posterior vena cava were realized at least four days in advance. The [3H]8-OH-DPAT results were obtained in vitro on adjacent coronal sections to the one used for the p-[18F]MPPF autoradiography. Quantitative densitometry was employed to compare the values obtained in relevant brain structures (frontal cortex, lateral septum, hippocampus, dorsal raphe, entorhinal cortex and cerebellum). The plot of the p-[18F]MPPF values obtained for each structure against the [3H]8-OH-DPAT results displayed a significant linear correlation. These results demonstrate that from a qualitative as well as quantitative point of view, the binding of p-[18F]MPPF is totally comparable to the one of [3H]8-OH-DPAT. Supported by grants from INSERM/CGRI and FNRS Belgium. [less ▲]

Detailed reference viewed: 32 (5 ULg)
Full Text
Peer Reviewed
See detailSolid phase extraction : An alternative to the use of rotary evaporators for solvent removal in the rapid formulation of PET radiopharmaceuticals
Lemaire, Christian ULg; Plenevaux, Alain ULg; Aerts, Joël ULg et al

in Journal of Labelled Compounds & Radiopharmaceuticals (1999), 42(1), 63-75

Solid phase extraction (SPE) was used for the formulation of several radiopharmaceuticals. The method involves dilution of the previously purified HPLC compound with water, trapping of the activity on an ... [more ▼]

Solid phase extraction (SPE) was used for the formulation of several radiopharmaceuticals. The method involves dilution of the previously purified HPLC compound with water, trapping of the activity on an SPE bed, washing off the support, elution of the radiopharmaceutical with a small volume of ethanol (<1 mL) and dilution with sterile isotonic saline solution. Recovery of the radiopharmaceuticals was always higher than 97%. Two different methods of automation were developed for the formulation of [11C] and [18F]radiopharmaceuticals. In all cases, organic solvent levels in the injectable solution were below the recommended limits. This fast (3-6 min.) and easy to automate process can be considered as an alternative to the conventional methods (rotary evaporators). Copyright © 1999 John Wiley [less ▲]

Detailed reference viewed: 65 (6 ULg)
Peer Reviewed
See detailMetabolism of no-carrier-added 2-[18F]fluoro-L-tyrosine in free mooving rats.
Aerts, Joël ULg; Plenevaux, Alain ULg; Lemaire, Christian ULg et al

in Society for Neuroscience / Abstracts (1998), 24

Detailed reference viewed: 12 (2 ULg)
Full Text
Peer Reviewed
See detailHigh-yield radiosynthesis and preliminary in vivo evaluation of p-[18F]MPPF, a fluoro analog of WAY-100635.
Le Bars, Didier; Lemaire, Christian ULg; Ginovart, N. et al

in Nuclear Medicine & Biology (1998), 25(4), 343-50

No-carrier-added 4-[18F]fluoro-N-[2-[1-(2-methoxyphenyl)-1 piperazinyl]ethyl-N-2-pyridinyl-benzamide (p-[18F]MPPF) was synthesized by nucleophilic substitution of the corresponding nitro compound in the ... [more ▼]

No-carrier-added 4-[18F]fluoro-N-[2-[1-(2-methoxyphenyl)-1 piperazinyl]ethyl-N-2-pyridinyl-benzamide (p-[18F]MPPF) was synthesized by nucleophilic substitution of the corresponding nitro compound in the presence of Kryptofix 222 and K2CO3 by microwave heating (3 min, 500 W) using a remotely controlled radiosynthesis. Baseline separation of p-[18F]MPPF from the nitro derivative was performed on a semipreparative HPLC C18 column. After Sep-Pak formulation, the radiopharmaceutical was obtained with a radiochemical yield of 25% (EOS) in about 70 min. Specific radioactivity averaged between 1-5 Ci/micromol EOS. Labelling of the ortho and meta derivatives was also attempted. Brain uptake of p-[18F]MPPF was studied with PET on fluothane-anesthetized cats. Following intravenous injection of p-[18F]MPPF, high accumulation of radioactivity was observed in the hippocampus and cerebral cortex. Low levels of radioactivity were observed in cerebellum. At 30 min, the mean hippocampus/cerebellum and cortex/cerebellum ratios were 5 and 3.8, respectively. The accumulation of the tracer was blocked by prior administration of reference WAY-100635, demonstrating the specificity of the ligand. [less ▲]

Detailed reference viewed: 43 (7 ULg)
Peer Reviewed
See detailMétabolisme du p-[18]MPPF (antagoniste 5-HT1A) chez le rat
Plenevaux, Alain ULg; Aerts, Joël ULg; Lemaire, Christian ULg et al

Poster (1997, May 29)

Detailed reference viewed: 10 (0 ULg)
Peer Reviewed
See detailMétabolisme de la 6-fluoro-L-tyrosine chez le rat
Aerts, Joël ULg; Plenevaux, Alain ULg; Lemaire, Christian ULg et al

Poster (1997, May 29)

Detailed reference viewed: 6 (1 ULg)
Full Text
Peer Reviewed
See detailLe p-[18F]MPPF: un nouveau ligand pour l'étude par TEP des récepteurs 5-HT1A
Ginovart, Nathalie; Le Bars, Didier; Lemaire, Christian ULg et al

Poster (1997, May 25)

Detailed reference viewed: 16 (0 ULg)
Peer Reviewed
See detailMicrowave improved synthesis of p-[18F]MPPF, 5-HT1A antagonist and PET sudies on cat brain.
Le Bars, D.; Ginovart, N.; Lemaire, Christian ULg et al

in Journal of Labelled Compounds & Radiopharmaceuticals (1997), 40

Detailed reference viewed: 11 (1 ULg)
Peer Reviewed
See detailSynthesis of [18F]FDG with alkaline hydrolysis on a low polarity solid phase support.
Lemaire, Christian ULg; Damhaut, Ph.; Lauricella, Benjamino ULg et al

in Journal of Labelled Compounds & Radiopharmaceuticals (1997), 40

Detailed reference viewed: 22 (4 ULg)
Peer Reviewed
See detailMetabolism of no carrier added 2-[18F]fluoro-L-tyrosine in free moving rats.
Aerts, Joël ULg; Plenevaux, Alain ULg; Lemaire, Christian ULg et al

in Journal of Labelled Compounds & Radiopharmaceuticals (1997), 40

Detailed reference viewed: 6 (0 ULg)
Peer Reviewed
See detailTissue distribution, autoradiography and metabolism in rats of p-[18F]MPPF: 5-HT1A antagonist.
Plenevaux, Alain ULg; Aerts, Joël ULg; Lemaire, Christian ULg et al

in Journal of Labelled Compounds & Radiopharmaceuticals (1997), 40

Detailed reference viewed: 6 (0 ULg)
Peer Reviewed
See detailHigh yield radiosynthesis of p-[F-18]MPPF, 5-HT1A antagonist, and PET studies in cat brain.
Le Bars, D.; Lemaire, Christian ULg; Plenevaux, Alain ULg et al

in Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine (1997), 38

Detailed reference viewed: 17 (2 ULg)
Peer Reviewed
See detailEvaluation of p-[F-18]MPPF, 5-HT1A antagonist, in rats: tissue distribution, autoradiography and metabolism.
Plenevaux, Alain ULg; Aerts, Joël ULg; Lemaire, Christian ULg et al

in Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine (1997), 38

Detailed reference viewed: 9 (1 ULg)
Peer Reviewed
See detailS-, N- and O-[11C]methylations of a Nor precursor adsorbed on Al2O3/KF.
Schmitz, F.; Plenevaux, Alain ULg; Del Fiore, G. et al

in Journal of Labelled Compounds & Radiopharmaceuticals (1995), 37

Detailed reference viewed: 7 (0 ULg)
Peer Reviewed
See detail[1-11C]Bromoethane: an alternative to the use of [1-11C]iodoethane.
Schmitz, F.; Del Fiore, G.; Plenevaux, Alain ULg et al

in Journal of Labelled Compounds & Radiopharmaceuticals (1995), 37

Detailed reference viewed: 89 (4 ULg)